PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2007 September; 8(3): E88–E91.
Published online 2007 August 3. doi:  10.1208/pt0803062
PMCID: PMC2750558

In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: A technical note

Conclusion

The in situ gel formulation of buprenorphine showed sustained drug release for a prolonged period of time. The drug release from RG 502 followed a linear pattern throughout the dissolution without any significant burst release. The amount of buprenorphine released during the first 30 minutes, irrespective of the type of Resomer or dissolution medium, was less than 3%. Drug release continued over 55 days in phosphate buffer and 35 days in Tween 80. The in vitro dissolution method developed during this study was capable of identifying formulation differences and thus will be useful for routine drug delivery research, particularly in situ gel formulation development research. In situ gel formulations are routinely compared using animal models,21, so development of such an in vitro method will expedite formulation evaluation.

Keywords: In situ gel, buprenorphine, PLGA, dissolution, drug abuse

Full Text

The Full Text of this article is available as a PDF (156K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Mello NK, Mendelson JH. Buprenorphine suppresses heroin use by heroin addicts. Science. 1980;207:657–659. doi: 10.1126/science.7352279. [PubMed] [Cross Ref]
2. Schottenfeld RS, Pakes JR, Kosten TR. Prognostic factors in buprenorphine-versus methadone-maintained patients. J Nerv Ment Dis. 1998;186:35–43. doi: 10.1097/00005053-199801000-00006. [PubMed] [Cross Ref]
3. Rosen MI, Wallace EA, Mcmahon TJ, et al. Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend. 1994;35:141–149. doi: 10.1016/0376-8716(94)90121-X. [PubMed] [Cross Ref]
4. Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT. Bioavailability of sublingual buprenorphine. J. Clin Pharmacol. 1997;37:31–37. doi: 10.1177/009127009703700106. [PubMed] [Cross Ref]
5. Gaitini L, Moskovitz B, Katz E, Vaisberg A, Vaida S, Nativ O. Sublingual buprenorphine compared to morphine delivered by a patientcontrolled analgesia system as postoperative analgesia after prostatectomy. Urol Int. 2007;57:227–229. doi: 10.1159/000100016. [PubMed] [Cross Ref]
6. Kuhlman JJ, Lalani S, Magluilo J, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol. 2007;20:369–378. [PubMed]
7. Lindhardt K, Ravn C, Gizurarson S, Bechgaard E. Intranasal absorption of buprenorphine—in vivo bioavailability study in sheep. Int J Pharm. 2000;205:159–163. doi: 10.1016/S0378-5173(00)00499-3. [PubMed] [Cross Ref]
8. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750–2755. doi: 10.1001/jama.267.20.2750. [PubMed] [Cross Ref]
9. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant, use of buprenorphine and benzodiazepines. Addiction. 1998;93:1385–1392. doi: 10.1046/j.1360-0443.1998.93913859.x. [PubMed] [Cross Ref]
10. Resnick RB, Resnick E, Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:531–538. doi: 10.1016/0278-5846(91)90028-Y. [PubMed] [Cross Ref]
11. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569–580. doi: 10.1038/clpt.1994.71. [PubMed] [Cross Ref]
12. Mello NK, Lukas SE, Kamien JB, Mendelson JH, Drieze J, Cone EJ. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 1992;260:1185–1193. [PubMed]
13. Pickworth WB, Johnson RE, Holicky BA, Cone E. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther. 1993;53:570–576. doi: 10.1038/clpt.1993.72. [PubMed] [Cross Ref]
14. Mandal TK. Development of biodegradable drug delivery system to treat addiction. Drug Dev Ind Pharm. 1999;25:773–779. doi: 10.1081/DDC-100102237. [PubMed] [Cross Ref]
15. Resnick RB, Resnick E, Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts? Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:531–538. doi: 10.1016/0278-5846(91)90028-Y. [PubMed] [Cross Ref]
16. Radomsky ML, Brouwer G, Floy BJ, et al. The controlled release of ganirelix from the Atrigel injectable implant system. Proc Int Symp Control Rel Bioact Mater. 1993;20:458–459.
17. Mello NK, Lukas SE, Kamien JB, Mendelson JH, Drieze J, Cone EJ. The effects of chronic buprenorphine treatment on cocaine and food self-administration by rhesus monkeys. J Pharmacol Exp Ther. 1992;260:1185–1193. [PubMed]
18. Pickworth WB, Johnson RE, Holicky BA, Cone EJ. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther. 1993;53:570–576. doi: 10.1038/clpt.1993.72. [PubMed] [Cross Ref]
19. Ruel-Gariepy E, Shive M, Bichara A, et al. A thermosensitive chitosan-based, hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm. 2004;57:53–63. doi: 10.1016/S0939-6411(03)00095-X. [PubMed] [Cross Ref]
20. Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201–230. doi: 10.1023/B:PHAM.0000016235.32639.23. [PubMed] [Cross Ref]
21. Koizumi A, Fujii M, Kondoh M, Watanabe Y. Effect of N-methyl-2-pyrrolidone on skin permeation of estradiol. Eur J Pharm Biopharm. 2004;57:473–478. doi: 10.1016/j.ejpb.2003.12.006. [PubMed] [Cross Ref]
22. Ravivarapu HB, Moyer KL, Dunn RL. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS PharmSciTech [serial online] 2000;1:E1–E1. doi: 10.1208/pt010101. [PMC free article] [PubMed] [Cross Ref]
23. The National Alliance of Advocate for Buprenorphine Treatment. Suboxone (CIII). Available at: http://www.naabt.org/documents/packageinsert.pdf. Accessed: July 26, 2007.
24. Abdou HM. Effect of the test parameters on dissolution rate. In: Abdou HM, editor. Dissolution, Bioavailability, and Bioequivalence. Easton, PA: Mack Publishing Co; 1989. pp. 195–195.
25. Lagrange F, Pehourcq F, Baumevieille M, Begaud B. Determination of buprenorphine in plasma by liquid chromatography: application to heroin-dependent subjects. J Pharm Biomed Anal. 1998;16:1295–1300. doi: 10.1016/S0731-7085(97)00139-8. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists